Atherothrombosis, Coronary Artery Disease, Peripheral Arterial Disease
Conditions
Brief summary
NEAT is an observational cohort (Prospective registry of real world data) of patients with coronary and peripheral artery disease in an outopatient setting.
Detailed description
National multicenter registry in Brazil with initial plan of 25 sites from the 5 Brazilian regions. It will be coordinated by HCOR Research Institute which will perform regulatory, data and site management beyond academic leadership.NEAT is an observational cohort (Prospective registry of real world data) of patients with coronary and peripheral artery disease in an outopatient setting with 12 months of follow-up with collection of data at baseline, 6 months and 12 months.
Interventions
None listed
Sponsors
Bayer
Hospital do Coracao
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients ≥45 years followed in ambulatory setting with ≥1 of the following 3 criteria: 1. Documented coronary disease (≥1 criteria must apply): * Stable angina * History of Unstable Angina * History of coronary angioplasty/stenting * History of coronary artery bypass graft * Myocardial infarction within the last 20 years 2. Documented symptomatic Peripheral Arterial Disease (≥1 criteria must apply): * Previous aorto-femoral bypass surgery, limb bypass surgery, or percutaneous transluminal angioplasty revascularization of the iliac, or infra-inguinal arteries, or * Previous limb or foot amputation for arterial vascular disease, or * History of intermittent claudication and one or more of the following: 1) An ankle/arm blood pressure (BP) ratio \< 0.90, or 2) Significant peripheral artery stenosis (≥50%) documented by angiography, or by duplex ultrasound.
Exclusion criteria
* Patients from institutions that don't provide the Institutional Authorization Term, * Incapacity of follow-up in one year according to investigator judgment (severe neuropsychiatric condition, life expectancy \< 12 months)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of patients receiving evidence based therapies to reduce cardiovascular risk | Baseline | DOMAIN 1: Appropriate use of antithrombotic therapy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of patients receiving complete evidence based therapies to reduce cardiovascular risk | 6 and 12 months | Patient should receive all of the following to consider complete evidence based therapy: Appropriate use of antithrombotic therapy; Cholesterol control; Blood pressure control; Glycemic control / diabetes treatment; Weight control; Non-pharmacological intervention |
| Percentage of patients with complete control of risk factors (blood pressure, cholesterol and glycemia) | baseline, 06 and 12 months | blood pressure, cholesterol and glycemia levels at baseline, 06 and 12 months |
Countries
Brazil
Outcome results
None listed